TY - JOUR
T1 - European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
AU - Bruno, Benedetto
AU - Wäsch, Ralph
AU - Engelhardt, Monika
AU - Gay, Francesca
AU - Giaccone, Luisa
AU - D’Agostino, Mattia
AU - Rodríguez-Lobato, Luis-Gerardo
AU - Danhof, Sophia
AU - Gagelmann, Nico
AU - Kröger, Nicolaus
AU - Popat, Rakesh
AU - van de Donk, Niels W. C. J.
AU - Terpos, Evangelos
AU - Dimopoulos, Meletios A.
AU - Sonneveld, Pieter
AU - Einsele, Hermann
AU - Boccadoro, Mario
N1 - Funding Information:
LGRL as BITRECS fellow has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 754550 and from “La Caixa” Foundation. SD has received funding from the Mildred Scheel Early Career Center funded by the German Cancer Aid.
Funding Information:
LGRL as BITRECS fellow has received funding from the European Union?s Horizon 2020 research and innovation pro-gramme under the Marie Sklodowska-Curie grant agreement No 754550 and from ?La Caixa? Foundation. SD has received funding from the Mildred Scheel Early Career Center funded by the German Cancer Aid.
Publisher Copyright:
© 2021 Ferrata Storti Foundation.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Chimeric antigen receptor (CAR) T cells (CAR-T) have dramatically changed the treatment landscape of B-cell malignancies, providing a potential cure for relapsed/refractory patients. Long-term responses in patients with acute lymphoblastic leukemia and non Hodgkin lymphomas have encouraged further development in myeloma. In particular, B-cell maturation antigen (BCMA)-targeted CAR-T have established very promising results in heavily pre-treated patients. Moreover, CAR-T targeting other antigens (i.e., SLAMF7 and CD44v6) are currently under investigation. However, none of these current autologous therapies have been approved, and despite high overall response rates across studies, main issues such as long-term outcome, toxicities, treatment resistance, and management of complications limit as yet their widespread use. Here, we critically review the most important pre-clinical and clinical findings, recent advances in CAR-T against myeloma, as well as discoveries in the biology of a still incurable disease, that, all together, will further improve safety and efficacy in relapsed/refractory patients, urgently in need of novel treatment options.
AB - Chimeric antigen receptor (CAR) T cells (CAR-T) have dramatically changed the treatment landscape of B-cell malignancies, providing a potential cure for relapsed/refractory patients. Long-term responses in patients with acute lymphoblastic leukemia and non Hodgkin lymphomas have encouraged further development in myeloma. In particular, B-cell maturation antigen (BCMA)-targeted CAR-T have established very promising results in heavily pre-treated patients. Moreover, CAR-T targeting other antigens (i.e., SLAMF7 and CD44v6) are currently under investigation. However, none of these current autologous therapies have been approved, and despite high overall response rates across studies, main issues such as long-term outcome, toxicities, treatment resistance, and management of complications limit as yet their widespread use. Here, we critically review the most important pre-clinical and clinical findings, recent advances in CAR-T against myeloma, as well as discoveries in the biology of a still incurable disease, that, all together, will further improve safety and efficacy in relapsed/refractory patients, urgently in need of novel treatment options.
UR - https://www.scopus.com/pages/publications/85107433010
UR - https://www.ncbi.nlm.nih.gov/pubmed/33792221
UR - https://www.scopus.com/pages/publications/85107433010
U2 - 10.3324/haematol.2020.276402
DO - 10.3324/haematol.2020.276402
M3 - Review article
C2 - 33792221
SN - 0390-6078
VL - 106
SP - 2054
EP - 2065
JO - Haematologica
JF - Haematologica
IS - 8
ER -
SDG 3 Good Health and Well-being